In conclusion, our retrospective study found that individualized selection of chemotherapy drugs combined with sequential immunotherapy based on BRCA1 mRNA expression level could control the disease and prolong survival of patients with unresectable pancreatic cancer. This evidence concerns the gene BRCA1 and pancreatic neoplasm.